Company intelligence / Profile preview
Ascendis Pharma
Copenhagen (Hellerup), Denmarkascendispharma.com ↗
- Ownership
- Public · ASND
- Development stage
- Phase 3
01
Overview
The company has submitted an NDA for TransCon CNP (navepegritide) for the treatment of children with achondroplasia in March 2025. They have multiple product candidates in clinical development across endocrinology rare diseases and oncology.
- Therapeutic areas
- OphthalmologyOncologyEndocrinology
- Modalities
- Prodrug therapieslong-acting prodrug therapies
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Mentioned collaborations with partners worldwide but specific partnerships not named
04
Financials
- Market cap
- $16.8B
- Total revenue
- $344.9M
- Enterprise value
- $16.4B
Beyond the preview
Go deeper on Ascendis Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ascendis Pharma.